Celsion Corporation (CLSN)
1.0700 -0.01 (-0.93%)
After hours: 4:54PM EDT
Chart Events
Performance Outlook
| Previous Close | 1.1000 |
| Open | 1.1200 |
| Bid | 1.0700 x 38800 |
| Ask | 1.0900 x 4000 |
| Day's Range | 1.0700 - 1.1300 |
| 52 Week Range | 0.4300 - 6.5000 |
| Volume | 1,015,732 |
| Avg. Volume | 14,034,201 |
| Market Cap | 93.482M |
| Beta (5Y Monthly) | 2.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6720 |
| Earnings Date | May 13, 2021 - May 17, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
Fair Value
Related Research
- GlobeNewswire
Celsion Management Participates in Alliance Global Partners Virtual Series
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management participated in Alliance Global Partners’ (AGP) Virtual Series on April 21, 2021. Michael H. Tardugno, Chairman, President and Chief Executive Officer, and Kursheed Anwar, Ph.D., Executive Vice President and Chief Scientific Officer were interviewed in a “Fireside Chat” by Matt Cross, Senior Biotech Research Analyst at AGP. The discussion focused on the Company’s lead product, GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer currently in Phase II studies, and on its PLACCINE vaccine development platform. Requests to listen to a replay can be made by emailing agpevents@allianceg.com. About Celsion Corporation Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies, DNA-based therapies and directed chemotherapies through clinical trials and eventual commercialization. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit www.celsion.com. Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Celsion Investor ContactJeffrey W. ChurchExecutive Vice President and CFO609-482-2455jchurch@celsion.com Or LHA Investor RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com # # #
- GlobeNewswire
CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING
Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering of 11,538,462 shares of common stock at a purchase price of $1.30 per share, resulting in net proceeds of $13.9 million, after deducting placement agents' fees but before expenses payable by the Company. A.G.P./Alliance Global Partners acted as the lead placement agent for the offering. JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agents for the offering. Celsion intends to use the net proceeds for general corporate purposes, including research and development activities, capital expenditures and working capital. This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-254515), previously filed with the Securities and Exchange Commission (the “SEC”) on March 19, 2021 and declared effective on March 30, 2021. The offering of the shares of common stock were made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering are filed with the SEC and are available on the SEC’s website at http://www.sec.gov or by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Celsion Corporation Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The Company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. For more information on Celsion, visit: http://www.celsion.com. (CLSN-FIN). Forward-Looking Statements Forward-looking statements in this news release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, statements relating to the offering and the use of proceeds therefrom, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in the Celsion's periodic filings with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Celsion Investor Contact Jeffrey W. ChurchExecutive Vice President and CFO609-482-2455jchurch@celsion.com or LHA Investor RelationsKim Sutton Golodetz212-838-3777kgolodetz@lhai.com # # #
- Benzinga
Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates
Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting on Women’s Cancer. GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform. OVATION 2 Study data now show R0 resections in 14 of 17 patients, or 82%, in the GEN-1 + Neoadjuvant Chemotherapy (NACT) arm, compared with seven of 12 patients, or 58%, in the NACT alone arm. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. The company recently has enrolled approximately 40% of the anticipated 110 patients into the OVATION 2 Study. To date, 29 patients have had their interval debulking surgery. Price Action: CLSN shares are up 1.5% at $1.4 in the premarket trading on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaSpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma PatientsQuest Diagnostics Offloads Interest in Q2 Solutions JV To IQVIA© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
